Key facts
- Notable investors include HSG (Hong Kong), CAS Star, Furong Capital, Shanghai Healthcare Capital, Ennovation Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Attec Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Attec Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Attec Biotech
Producer of protein degradation drugs based in Hangzhou, China. The company specialises in degradation compounds, autophagy pathway modulators, lysosomal trafficking enhancers, molecular glue libraries, bioactivity profiling tools, preclinical validation services and drug development pipeline, thereby enabling more effective treatment options through novel mechanisms of action in precision medicine.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2019
- Website
- attecbiotech.com/
- Ownership
- Privately Held (backing)
Attec Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Attec Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Attec Biotech in its N-PORT filings yet. We sweep new filings monthly.